Q3 2018 EPS Estimates for Charles River Laboratories Intl. Inc (CRL) Lowered by KeyCorp

Charles River Laboratories Intl. Inc (NYSE:CRL) – Stock analysts at KeyCorp decreased their Q3 2018 earnings estimates for shares of Charles River Laboratories Intl. in a research report issued to clients and investors on Wednesday, August 8th. KeyCorp analyst D. Hooker now forecasts that the medical research company will earn $1.37 per share for the quarter, down from their previous estimate of $1.45. KeyCorp has a “Overweight” rating and a $130.00 price target on the stock. KeyCorp also issued estimates for Charles River Laboratories Intl.’s Q4 2018 earnings at $1.52 EPS, FY2018 earnings at $5.89 EPS and FY2019 earnings at $6.25 EPS.

Other equities research analysts have also recently issued research reports about the company. Zacks Investment Research cut Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Tuesday, May 15th. Barclays boosted their target price on Charles River Laboratories Intl. from $110.00 to $120.00 and gave the company an “equal weight” rating in a research note on Thursday, August 9th. Jefferies Financial Group boosted their target price on Charles River Laboratories Intl. from $140.00 to $145.00 and gave the company a “buy” rating in a research note on Thursday, August 9th. TheStreet upgraded Charles River Laboratories Intl. from a “c+” rating to a “b+” rating in a research note on Thursday, May 10th. Finally, Mitsubishi UFJ Financial Group began coverage on Charles River Laboratories Intl. in a research note on Friday, April 20th. They issued a “neutral” rating and a $115.00 target price on the stock. Six research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $122.00.



NYSE CRL opened at $120.14 on Monday. The company has a market capitalization of $5.79 billion, a price-to-earnings ratio of 22.77, a PEG ratio of 1.51 and a beta of 0.66. The company has a current ratio of 1.72, a quick ratio of 1.48 and a debt-to-equity ratio of 1.52. Charles River Laboratories Intl. has a 52 week low of $96.70 and a 52 week high of $130.66.

Charles River Laboratories Intl. (NYSE:CRL) last released its earnings results on Wednesday, August 8th. The medical research company reported $1.62 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.46 by $0.16. The firm had revenue of $585.30 million for the quarter, compared to analysts’ expectations of $570.65 million. Charles River Laboratories Intl. had a return on equity of 25.26% and a net margin of 6.38%. The business’s quarterly revenue was up 24.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.29 EPS.

In other Charles River Laboratories Intl. news, Director George Massaro sold 300 shares of the business’s stock in a transaction that occurred on Monday, June 25th. The stock was sold at an average price of $115.55, for a total transaction of $34,665.00. Following the transaction, the director now owns 14,037 shares of the company’s stock, valued at approximately $1,621,975.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David Ross Smith sold 1,249 shares of the business’s stock in a transaction that occurred on Monday, August 13th. The stock was sold at an average price of $120.05, for a total value of $149,942.45. Following the transaction, the insider now directly owns 13,690 shares in the company, valued at approximately $1,643,484.50. The disclosure for this sale can be found here. Insiders have sold a total of 33,258 shares of company stock worth $4,001,244 in the last ninety days. Insiders own 2.10% of the company’s stock.

Several large investors have recently bought and sold shares of the business. Zacks Investment Management increased its position in shares of Charles River Laboratories Intl. by 6.3% during the 2nd quarter. Zacks Investment Management now owns 17,612 shares of the medical research company’s stock worth $1,977,000 after purchasing an additional 1,037 shares during the last quarter. Highland Capital Management LP increased its holdings in shares of Charles River Laboratories Intl. by 67.8% during the 2nd quarter. Highland Capital Management LP now owns 4,332 shares of the medical research company’s stock worth $486,000 after acquiring an additional 1,750 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Charles River Laboratories Intl. during the 2nd quarter worth approximately $460,000. Natixis acquired a new position in shares of Charles River Laboratories Intl. during the 2nd quarter worth approximately $4,830,000. Finally, Voya Investment Management LLC increased its holdings in shares of Charles River Laboratories Intl. by 10.5% during the 2nd quarter. Voya Investment Management LLC now owns 114,394 shares of the medical research company’s stock worth $12,842,000 after acquiring an additional 10,847 shares during the last quarter. 98.02% of the stock is currently owned by hedge funds and other institutional investors.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Story: Google Finance Portfolio

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply